Guggenheim Maintains Buy on Relay Therapeutics, Raises Price Target to $22
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Brad Canino maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $15 to $22.
Guggenheim analyst Brad Canino maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $15 to $22.